tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

CNS Pharmaceuticals Announces Reverse Stock Split

Story Highlights
  • CNS Pharmaceuticals announced a 1-for-12 reverse stock split effective July 22, 2025.
  • The reverse split reduced authorized shares and adjusted outstanding warrants proportionately.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
CNS Pharmaceuticals Announces Reverse Stock Split

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

CNS Pharmaceuticals ( (CNSP) ) has shared an announcement.

On July 17, 2025, CNS Pharmaceuticals, Inc. announced a 1-for-12 reverse stock split of its common stock, which became effective on July 22, 2025. This corporate action reduced the number of authorized common shares from 300 million to 25 million and adjusted all outstanding warrants and equity-based awards proportionately. The reverse split aims to consolidate shares, affecting all stockholders uniformly without altering their percentage ownership, except for fractional shares, for which cash payments will be made.

The most recent analyst rating on (CNSP) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on CNS Pharmaceuticals stock, see the CNSP Stock Forecast page.

Spark’s Take on CNSP Stock

According to Spark, TipRanks’ AI Analyst, CNSP is a Underperform.

CNS Pharmaceuticals faces significant challenges in achieving profitability and financial stability, as evidenced by its financial performance. Technical indicators suggest the stock is oversold, offering potential for stabilization or recovery. However, the absence of revenue and earnings complicates valuation, highlighting the high-risk, high-reward scenario typical of early-stage biotech firms. Investors should weigh the potential scientific breakthroughs against the financial risks.

To see Spark’s full report on CNSP stock, click here.

More about CNS Pharmaceuticals

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing anti-cancer drug candidates for treating primary and metastatic cancers of the brain and central nervous system. Their drug candidate, TPI 287, is an abeotaxane that stabilizes microtubules and inhibits cell division, with potential efficacy in crossing the blood-brain barrier to treat CNS tumors.

Average Trading Volume: 1,725,988

Technical Sentiment Signal: Sell

Current Market Cap: $4.37M

See more insights into CNSP stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1